views

IXICO – next year “expects to achieve double digit revenue growth”, but what about this year and the bottom-line?

Medical analytics company IXICO plc (IXI) has issued a trading update commencing that it “reconfirms its revenue expectations of £7 million for the year to 30 September 2023 and announces that it now expects to achieve double digit revenue growth in the year to 30 September 2024”. So what of this currently helping the shares up to 26.5p?

views

IXICO – “contract win”. Is it?, and what about the contract loss and financial outlook?

Medical analytics company IXICO plc (IXI) has announced that it “has been selected by a leading global pharmaceutical company, and new client, to provide MRI imaging services for an early phase clinical trial”. So what’s the detail, with the shares currently up approaching 4% at 26.5p in response?

views

IXICO – “a strong set of financial results”, Really?

Medical analytics company IXICO plc (IXI) has announced what it emphasises as “a strong set of financial results… strong balance sheet supports the execution of our renewed five-year strategic plan”. So what of a share price response currently approaching 6% lower at 27.5p, to give a £13.2 million market cap?

NEWSFLOW

IXICO (#IXI) – expects FY EBITDA to “comfortably exceed previous guidance of £1.2 million”. What about the bottom-line though?

views

IXICO – ahead of expectations, but set not to be so for long...

Medical analytics company IXICO plc (IXI) has announced results for its half-year ended 31st March 2022, including that it now anticipates that it will “materially exceed” market profit expectations for the full year. So what of a current 37.5p share price, down more than 9%?!...

views

IXICO – contract award, but how’s the cash burn?...

Biopharmaceutical data analytics company IXICO (IXI) has announced it has been selected for an open-label Phase I/II dose finding study, emphasising it “reflects the confidence of our clients in the use of our services”. So what of a share price slightly ahead to 43.5p, but comparing to 58.5p in December?...

views

IXICO – full-year results, ‘resilience built in’?

Biopharmaceutical data analytics company IXICO (IXI) has announced results for its year ended 30th September 2021 and the shares are currently more than 16% higher to 58.5p. However that compares to circa 84.5p when I previously wrote in October, so what’s the story now?...

views

IXICO – emphasises “ahead of market expectations”, but what does that mean financially and what’s to come?...

Biopharmaceutical data analytics company IXICO (IXI) has made a trading update including that year ended 30th September 2021 EBITDA is “expected to be materially ahead of market expectations of £1.2 million and prior year (2020: £1.3 million)”. Why then is the share price little changed at circa 84.5p?...

NEWSFLOW

IXICO (#IXI) – FY update, one-offs & investment to hinder bottom-line this year

views

IXICO – “successfully grown its pipeline of new opportunities”, so why are the shares further lower?...

Having been above 100p as recently as April, shares in biopharmaceutical data analytics company IXICO (IXI) are currently further lower at 72p despite a trading update including that “the company has successfully grown its pipeline of new opportunities”. So what’s going on?...